|
Nov 13
|
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
|
|
Oct 10
|
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
|
|
Oct 9
|
MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges
|
|
Jul 17
|
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
|
|
May 29
|
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
|
|
May 23
|
With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
|
|
May 12
|
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 MaxCyte Inc Earnings Call
|
|
May 8
|
MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
|
|
May 7
|
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
|
|
Apr 17
|
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
|
|
Apr 10
|
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
|
|
Apr 2
|
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
|
|
Mar 17
|
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
|
|
Mar 14
|
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
|
|
Mar 14
|
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
|
|
Mar 13
|
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
|
|
Mar 13
|
11 Oversold Healthcare Stocks To Buy Right Now
|
|
Mar 12
|
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
|